



August 25, 2003

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF VERMONT

ALZA CORPORATION, et al. *
*
V *
*
MYLAN LABORATORIES, INC. * Civil File No. 02-20

TRIAL BY COURT
Monday, August 25, 2003 - Volume II
Burlington, Vermont

BEFORE:

THE HONORABLE WILLIAM K. SESSIONS, III
Chief District Judge

APPEARANCES:

JEFFREY I. D. LEWIS, ESQ., KARLA G. SANCHEZ, ESQ.
GREGORY DISKANT, ESQ., Patterson, Webb & Tyler, LLP
1133 Avenue of the Americas
New York, New York; Attorneys for the Plaintiffs

WALTER E. JUDGE, JR., ESQ., Downs, Rachlin & Martin,
PLLC

199 Main Street, Courthouse Plaza
Burlington, Vermont; Attorney for the Defendant
ANTHONY FIGG, ESQ. and SHARON L. DAVIS, ESQ., JOSEPH
HYNDS, ESQ., Rothwell, Figg, Ernst & Manbeck, P.C.
1425 K Street, N.W., Suite 800
Washington, DC.; Attorneys for the Defendant

CAPITOL COURT REPORTERS, INC.
P.O. BOX 329
BURLINGTON, VERMONT 05402-0329
(800/802) 863-6067

(802) 879-4736 (Fax)
E-Mail: Reporter@Together.Net
CAPITOL COURT REPORTERS, INC.
(802) 863-6067

1 Q. And on the last page of the document, the
2 conclusion is that Alza had successfully addressed the
3 abuse issue. Do you see that?

4 A. Yes.

5 Q. And you mentioned earlier on in your
6 testimony, that one of the development goals of Alza was
7 minimizing the amount of drug in each patch. Is that how
8 Alza successfully addressed the abuse issue?

9 A. Yes, it is.

10 Q. Now after these meetings, was duragesic
11 eventually approved?

12 A. Yes, it was.

13 Q. And when did that happen?

14 A. It was on August 7, 1990.

15 Q. And for what uses was duragesic approved?

16 A. It was approved for the treatment --
17 management of chronic pain in patients who required round
18 the clock dosing and couldn't be managed by any lesser
19 type analgesics.

20 Q. I would like to show you what's been marked as
21 Plaintiff's Exhibit 529. Can you tell me what that is?

22 A. Yes. That's the current duragesic package
23 insert.

24 Q. And I move to admit both Plaintiff's Exhibit
25 529 and 515?